Biodesix (BDSX) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Buy | $35.00 from $27.00 | Aug 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $27.00 from $26.00 | Aug 6, 2026 |
| Roth Capital | Initiated Coverage | Buy | $32.00 | Jun 25, 2026 |
| Canaccord Genuity | Maintained | Buy | $27.00 from $22.00 | Jun 18, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $26.00 | Jun 15, 2026 |
| Canaccord Genuity | Maintained | Buy | $22.00 from $20.00 | May 5, 2026 |
| William Blair | Upgraded | Market Perform → Outperform | — | Feb 27, 2026 |
| Canaccord Genuity | Maintained | Buy | $20.00 | Feb 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $20.00 from $30.00 | Sep 19, 2025 |
| Scotiabank | Maintained | Sector Outperform | $2.00 from $3.00 | May 21, 2025 |
| William Blair | Downgraded | Outperform → Market Perform | — | May 14, 2025 |
| Canaccord Genuity | Maintained | Buy | $1.50 from $2.50 | May 14, 2025 |
| Lake Street | Maintained | Buy | $2.00 from $3.00 | May 14, 2025 |
| Craig-Hallum | Maintained | Buy | $1.50 from $3.00 | May 14, 2025 |
| Canaccord Genuity | Maintained | Buy | $2.50 from $3.50 | Apr 29, 2025 |
| Scotiabank | Initiated Coverage | Sector Outperform | $3.00 | Sep 16, 2024 |
| Craig-Hallum | Initiated Coverage | Buy | $3.00 | Jul 26, 2024 |
| TD Cowen | Initiated Coverage | Buy | $2.80 | May 13, 2024 |
| Lake Street | Initiated Coverage | Buy | $3.00 | May 3, 2024 |
| Canaccord Genuity | Maintained | Buy | $3.50 | Mar 4, 2024 |
Frequently asked questions
What is the price target for BDSX stock?
The average 12-month analyst price target for Biodesix (BDSX) is $31.33, with a high estimate of $35.00 and a low of $27.00, across 3 analysts.
Is BDSX a buy, sell, or hold?
Analysts covering Biodesix currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BDSX?
The average price target of $31.33 implies 21.31% upside from the last price of $25.83.
What is the latest analyst rating on BDSX?
On Aug 10, 2026, Canaccord Genuity maintained Biodesix at Buy with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.